{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:54:02Z","timestamp":1774270442952,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,23]]},"DOI":"10.7759\/cureus.105692","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:56:56Z","timestamp":1774267016000},"source":"Crossref","is-referenced-by-count":0,"title":["Dose Up-Titration of a Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor for Markedly Elevated Lipoprotein(a) in a Patient With Familial Hypercholesterolemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Nobuaki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisako","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson E","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, Bor\u00e9n J. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol. 2024, 83:385-95. 10.1016\/j.jacc.2023.10.039","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01215-5","article-title":"Lipoprotein (a)-related inflammatory imbalance: a novel horizon for the development of atherosclerosis","volume":"26","author":"Qin T","year":"2024","unstructured":"Qin T, Ma TY, Huang K, Lu SJ, Zhong JH, Li JJ. Lipoprotein (a)-related inflammatory imbalance: a novel horizon for the development of atherosclerosis. Curr Atheroscler Rep. 2024, 26:383-94. 10.1007\/s11883-024-01215-5","journal-title":"Curr Atheroscler Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019, 139:e1082-143. 10.1161\/CIR.0000000000000625","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag092","article-title":"Lipoprotein(a)-lowering therapies: a promising future (in press)","author":"Zhang J","year":"2026","unstructured":"Zhang J, Navar AM, Tokgozoglu L. Lipoprotein(a)-lowering therapies: a promising future (in press). Eur Heart J. 2026, ehag092. 10.1093\/eurheartj\/ehag092","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud IS","year":"2023","unstructured":"Alhomoud IS, Talasaz A, Mehta A, et al.. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies. Pharmacotherapy. 2023, 43:1051-63. 10.1002\/phar.2851","journal-title":"Pharmacotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5551\/jat.GL2022","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022","volume":"31","author":"Okamura T","year":"2024","unstructured":"Okamura T, Tsukamoto K, Arai H, et al.. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2024, 31:641-853. 10.5551\/jat.GL2022","journal-title":"J Atheroscler Thromb"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach F","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al.. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025, 46:4359-78. 10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/202213","article-title":"2024: the year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings","volume":"21","author":"Sosnowska B","year":"2025","unstructured":"Sosnowska B, Toth PP, Razavi AC, Remaley AT, Blumenthal RS, Banach M. 2024: the year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings. Arch Med Sci. 2025, 21:355-73. 10.5114\/aoms\/202213","journal-title":"Arch Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard BG","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024, 404:1255-64. 10.1016\/S0140-6736(24)01308-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2007.04.015","article-title":"Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg\/dL) on the risk of coronary heart disease","volume":"56","author":"Murase T","year":"2007","unstructured":"Murase T, Okubo M, Amemiya-Kudo M, Hiraga T, Oka J, Shimada M, Igarashi T. Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg\/dL) on the risk of coronary heart disease. Metabolism. 2007, 56:1187-91. 10.1016\/j.metabol.2007.04.015","journal-title":"Metabolism"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.12.015","article-title":"Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"180","author":"Gaw A","year":"2005","unstructured":"Gaw A, Murray HM, Brown EA. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis. 2005, 180:381-8. 10.1016\/j.atherosclerosis.2004.12.015","journal-title":"Atherosclerosis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas S","year":"2005","unstructured":"Tsimikas S, Brilakis ES, Miller ER, et al.. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005, 353:46-57. 10.1056\/NEJMoa043175","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(90)90093-x","article-title":"Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate","volume":"84","author":"Noma A","year":"1990","unstructured":"Noma A, Maeda S, Okuno M, Abe A, Muto Y. Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate. Atherosclerosis. 1990, 84:213-7. 10.1016\/0021-9150(90)90093-x","journal-title":"Atherosclerosis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue ML","year":"2019","unstructured":"O'Donoghue ML, Fazio S, Giugliano RP, et al.. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019, 139:1483-92. 10.1161\/CIRCULATIONAHA.118.037184","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention","volume":"115","author":"Konishi H","year":"2015","unstructured":"Konishi H, Miyauchi K, Kasai T, et al.. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol. 2015, 115:157-60. 10.1016\/j.amjcard.2014.10.015","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae341","article-title":"Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population","volume":"32","author":"Awad K","year":"2025","unstructured":"Awad K, Mahmoud AK, Abbas MT, Alsidawi S, Ayoub C, Arsanjani R, Farina JM. Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population. Eur J Prev Cardiol. 2025, 32:716-21. 10.1093\/eurjpc\/zwae341","journal-title":"Eur J Prev Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen SE","year":"2025","unstructured":"Nissen SE, Ni W, Shen X, et al.. Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025, 392:1673-83. 10.1056\/NEJMoa2415818","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas S","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al.. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020, 382:244-55. 10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls SJ","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al.. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2025, 333:222-31. 10.1001\/jama.2024.24017","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462427-dose-up-titration-of-a-proprotein-convertase-subtilisinkexin-type-9-inhibitor-for-markedly-elevated-lipoproteina-in-a-patient-with-familial-hypercholesterolemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:56:57Z","timestamp":1774267017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462427-dose-up-titration-of-a-proprotein-convertase-subtilisinkexin-type-9-inhibitor-for-markedly-elevated-lipoproteina-in-a-patient-with-familial-hypercholesterolemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}